These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34439136)

  • 1. Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients.
    Cavallo A; Iacovelli NA; Facchinetti N; Rancati T; Alfieri S; Giandini T; Cicchetti A; Fallai C; Ingargiola R; Licitra L; Locati L; Cavalieri S; Pignoli E; Romanello DA; Valdagni R; Orlandi E
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients.
    Orlandi E; Iacovelli NA; Rancati T; Cicchetti A; Bossi P; Pignoli E; Bergamini C; Licitra L; Fallai C; Valdagni R; Cavallo A
    Oral Oncol; 2018 Nov; 86():266-272. PubMed ID: 30409311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
    Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
    Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
    Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy.
    Lee TF; Fang FM
    Radiother Oncol; 2013 Mar; 106(3):352-8. PubMed ID: 23333019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors.
    Beetz I; Schilstra C; Burlage FR; Koken PW; Doornaert P; Bijl HP; Chouvalova O; Leemans CR; de Bock GH; Christianen ME; van der Laan BF; Vissink A; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):86-93. PubMed ID: 21632133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LASSO NTCP predictors for the incidence of xerostomia in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
    Lee TF; Liou MH; Huang YJ; Chao PJ; Ting HM; Lee HY; Fang FM
    Sci Rep; 2014 Aug; 4():6217. PubMed ID: 25163814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma.
    Cheng JC; Chao KS; Low D
    Int J Cancer; 2001 Apr; 96(2):126-31. PubMed ID: 11291096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function.
    Kwong DL; Pow EH; Sham JS; McMillan AS; Leung LH; Leung WK; Chua DT; Cheng AC; Wu PM; Au GK
    Cancer; 2004 Oct; 101(7):1584-93. PubMed ID: 15378492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience.
    Lee N; Xia P; Quivey JM; Sultanem K; Poon I; Akazawa C; Akazawa P; Weinberg V; Fu KK
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):12-22. PubMed ID: 12007936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - A prospective cohort analysis.
    Sommat K; Hussain A; Ong WS; Yit NLF; Khoo JBK; Soong YL; Wee JTS; Fong KW; Tan TWK
    Radiother Oncol; 2019 Sep; 138():149-157. PubMed ID: 31265972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional dosimetric evaluation of a conventional radiotherapy technique for treatment of nasopharyngeal carcinoma.
    Chau RM; Teo PM; Choi PH; Cheung KY; Lee WY
    Radiother Oncol; 2001 Feb; 58(2):143-53. PubMed ID: 11166865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer].
    Kuhnt T; Jirsak N; Müller AC; Pelz T; Gernhardt C; Schaller HG; Janich M; Gerlach R; Dunst J
    Strahlenther Onkol; 2005 Aug; 181(8):520-8. PubMed ID: 16044220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation.
    Kam MK; Chau RM; Suen J; Choi PH; Teo PM
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):145-57. PubMed ID: 12694833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Risk Prediction Model by LASSO for Radiation-Induced Xerostomia in Patients With Nasopharyngeal Carcinoma Treated With Comprehensive Salivary Gland-Sparing Helical Tomotherapy Technique.
    Teng F; Fan W; Luo Y; Xu S; Gong H; Ge R; Zhang X; Wang X; Ma L
    Front Oncol; 2021; 11():633556. PubMed ID: 33718219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary gland function in nasopharyngeal carcinoma before and late after intensity-modulated radiotherapy evaluated by dynamic diffusion-weighted MR imaging with gustatory stimulation.
    Shi D; Qian JJ; Fan GH; Shen JK; Tian Y; Xu L
    BMC Oral Health; 2019 Dec; 19(1):288. PubMed ID: 31864328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Infiltrating T Cell Receptor-Beta Repertoires are Linked to the Risk of Late Chemoradiation-Induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma.
    Wu L; Chung YL
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):165-176. PubMed ID: 30654091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.